Despite progress in treatment and supportive therapies, outcome of high-risk adult AML remains dismal with~20% of patients becoming long-term survivors. 1 Since the pretreatment genetics/cytogenetics of AML do not always anticipate the individual outcome, there is a strong rationale to implement laboratory techniques capable of exploring the quality of CR and allowing post-remission therapy to be optimally directed. 2 In this view, minimal residual disease (MRD) assessment promises to be a robust approach. It captures the diversities of the underlying genetic/cytogenetic features of AML and recapitulates other patient heterogeneities regarding drug bioavailability, metabolism and resistance.
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Since the pretreatment genetics/cytogenetics of AML do not always anticipate the individual outcome, there is a strong rationale to implement laboratory techniques capable of exploring the quality of CR and allowing post-remission therapy to be optimally directed. 2 In this view, minimal residual disease (MRD) assessment promises to be a robust approach. It captures the diversities of the underlying genetic/cytogenetic features of AML and recapitulates other patient heterogeneities regarding drug bioavailability, metabolism and resistance. 3 Multiparametric flow cytometry (MFC) is one of the leading techniques successfully exploited to quantify MRD in AML expressing leukemia-associated immunophenotypes (LAIP). 4, 5 This assay applies to the vast majority of patients after chemotherapy-induced morphologic CR and has been shown to predict the clinical outcome when measured at several time points, potentially prompting prospective treatment adjustments.
Recent studies have demonstrated that pretransplant MRD levels negatively affect post-transplant outcome. 2, [6] [7] [8] Years ago, we showed that MRD persistence at the end of consolidation was associated with an unfavorable outcome and that autologous stem cell transplantation (AuSCT) was not able to alter such an unfavorable course. 9 More recently, other authors have extended this observation to either pediatric or adult patients receiving allogeneic stem cell transplantation (ASCT), showing that pretransplant MRD is a major determinant of prognosis, regardless of the occurrence of graft-versus-leukemia (GVL). 10 Nevertheless, whether MRD positivity is an indication or a contraindication to deliver ASCT is still a matter of debate. On the basis of these premises, we analyzed a retrospective series of MRD-positive adults with AML who were submitted to ASCT. Our aim was to evaluate the impact of pretransplant MRD status on overall survival (OS) and DFS.
We analyzed 230 consecutive patients achieving CR after the induction cycle of intensive EORTC/GIMEMA protocols and who harbored in their leukemic cells a LAIP suitable for MRD monitoring. The present series represents an extension of a cohort of patients already analyzed for different purposes and reported previously. 4, 5 Following our previous experience, MRD positivity was defined if ⩾ 3.5 × 10 − 4 (0.035%) residual leukemic cells (RLCs) were detected in the BM upon full hematological recovery after consolidation cycle. 4, 5 According to this definition, 176/230 patients (76.5%) were classified as MRD positive (MRD pos ) and 54/230 (23.5%) as MRD negative (MRD neg ). In the overall series, 84/230 patients (36.5%) received no transplant because of age, poor performance status or insufficient stem cell harvest, 28/230 (12.2%) relapsed before transplant delivery whereas 118/230 (51.3%) underwent ASCT (N = 50) or AuSCT (N = 68) in first CR.
For the purpose of the present analysis, we focused on the 81 patients who tested MRD pos and who were submitted to ASCT (N = 45) or AuSCT (N = 36), respectively. The same analysis was not feasible for MRD neg patients due to the low numbers in the ASCT group (N = 5), preventing any statistical significance from being demonstrated. The clinico-biological characteristics of the patients are detailed in Table 1 . The two groups were balanced regarding white blood cell count (WBCc), ELN risk category, FLT3 and NPM1 mutational status. Karyotypic analysis was available in 77 (95%) out of 81 patients. Intermediate risk category accounted for 78% Table 1 . Clinical characteristics of patients
ASCT
AuSCT All patients P-value (60/77) equally distributed between the ASCT and AuSCT groups. Only 1 patient out of 45 submitted to ASCT (2%) was older than 60 years as compared with 6/36 (17%) of those undergoing AuSCT (P = 0.020). Among the 45 patients submitted to ASCT, 25 (55.6%) received an HLA-matched sibling transplant, whereas for 20 (44.4%), sources of stem cells were MUD (N = 11) or haploidentical donor (N = 9). Patients receiving ASCT and AuSCT differed significantly in terms of survival estimates. In fact, OS and DFS were 59.0 and 27.5% (P = 0.0057), and 59.7 and 19.4% (P = 0.0001), respectively. Overall, 5-year CIR was significantly higher for the AuSCT as compared with the ASCT group (72.2 vs 17.9%, P o 0.0001), whereas non-relapse mortality (NRM) was higher for ASCT as compared with AuSCT group (22.4 vs 8.3%, P = 0.1).
Thus, we confirmed that AuSCT does not alter the negative prognosis of MRD pos status. In this view, MRD pos patients represent a high-risk category that is not manageable with AuSCT, but which might benefit from ASCT and the related GVL long-term control of the disease. In fact, recent meta-analyses of large prospective trials indicate that the beneficial effect of ASCT takes place in patients whose risk of relapse exceeds 35-40% or in whom at least a 10% DFS benefit can be achieved as compared with a non-ASCT approach. 11, 12 Accordingly, in our series, MRD pos patients benefit from an OS and DFS advantage of 38% and 40% when treated by ASCT as compared with AuSCT, respectively ( Figure 1 ). Nevertheless, although ASCT is the most powerful tool nowadays available to treat high-risk AML, it appears to be unable to fully overcome the negative prognostic impact of MRD persistence. Pretransplant MRD positivity, assessed by a MFC 10-color assay in 253 pediatric and adult patients, was found to negatively affect the outcome and this impact was independent of other clinical variables such as CR1 or CR2, amount of RLCs (above or below 0.1%) and age. 7 In an attempt to investigate the reasons for ASCT failure in MRD pos patients, we asked whether a significant burden of MRD could counteract GVL effects. This assumption has already been addressed in two studies recruiting pediatric and adult patients. 13, 14 In both the studies, MRD pos patients were considered 'high positive' if the level of MRD was 41%. Even if the study of Leung also included high-risk ALL and the study of Anthias suffers from lack of consistent numbers in the group of MRD pos patients (N = 35), both the authors concluded that the outcome of patients harboring 41% MRD was worse as compared with those in whom, although above the threshold of negativity, a limited amount of MRD was detected. In our series, we observed that among MRD pos patients, ASCT conferred a significant survival advantage on those with 'low burden' MRD level (o 1%). At variance, patients submitted to AuSCT had a worse outcome regardless of MRD level (data not shown).
In the multivariate model, including all the 81 MRD pos patients, we challenged all the variables that were significant in the univariate analysis (age 460 years, type of transplant), or which were universally recognized as prognostic factors (WBCc, FLT3, NPM, karyotype, MRD). Transplant was considered as a timedependent covariate. Backward, forward and stepwise procedures for OS confirmed the model, including AuSCT vs ASCT (HR 0.44, 95% CI 0.24-0.80, P = 0.007). The same result was also observed for DFS, where the only selected variable was AuSCT vs ASCT (HR 0.33, 95% CI 0.18-0.59, P = 0.0002).
Taken together, this evidence may represent a background to guide the choice of ASCT based not on the availability of a matched sibling donor but rather on the real aggressiveness of the disease, therefore considering even alternative sources of stem cells. In the present series, almost half of ASCT were performed using alternative sources of stem cells.
In conclusion, MRD persistence before the transplant is a negative determinant of long-term outcome in adult AML patients. However, at variance with AuSCT, ASCT is the first choice to contrast the negative impact of MRD positivity, especially in those patients with 'low burden' MRD. We do believe that ASCT is not contraindicated in patients with pretransplant MRD persistence, and indeed, it allows rescue of a substantial proportion of these high-risk patients. 15 In future trials, these patients should be timely and prospectively addressed to this procedure, also considering alternative sources of stem cells for patients lacking a matched sibling donor. Further reduction in relapse risk is likely to be facilitated by novel strategies that can augment GVL effects. 
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